Assisted reproductive industry ushered in medical insurance support and domestic development

On April 16, 2024, Deppon Securities released an in-depth analysis report on the healthcare sector, which highlights the market growth potential of the assisted reproduction industry and its localization trend.

Detailed highlights of the report are summarized below:

Under the guidance of the National Medical Insurance Administration, four provinces and cities including Beijing, Guangxi, Inner Mongolia and Gansu have gradually included assisted reproductive technology in the scope of medical insurance reimbursement. With the convening of the National Two sessions this year, assisted reproductive technology has once again become the focus of attention of the public and policy makers. According to statistics released by the National Health Commission and the China Population Association, the penetration rate of assisted reproductive technology in China in 2021 is only 8.2%, compared with 32% in the United States, showing the huge growth potential of China in this field. The remission of the epidemic in 2023 has prompted more infertility patients to seek assisted reproduction services, and the industry is expected to gradually return to the pre-epidemic development level, with further growth expected.

Domestic assisted reproductive services have built a mature industrial chain. With the growing market demand and the continuous improvement of the medical security system, it is expected that the assisted reproduction industry will usher in the expansion of the market size and the acceleration of the localization process.